BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9856651)

  • 21. A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
    Au E; Koo WH; Tan EH; Ang PT
    J Chemother; 1996 Aug; 8(4):300-3. PubMed ID: 8873837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study.
    Adamo V; Scimone A; Maisano R; Altavilla G; Ferraro G; Laudani A; Pergolizzi S; Zanghì M
    J Chemother; 1999 Feb; 11(1):74-7. PubMed ID: 10078785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
    Gnad-Vogt SU; Hofheinz RD; Saussele S; Kreil S; Willer A; Willeke F; Pilz L; Hehlmann R; Hochhaus A
    Anticancer Drugs; 2005 Apr; 16(4):435-40. PubMed ID: 15746580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments in the treatment of gastric carcinoma.
    Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma.
    Parnes HL; Abrams JS; Tait N; Minford J; Allen SL; Duggan D; Aisner J
    J Natl Cancer Inst; 1991 Jul; 83(14):1017-20. PubMed ID: 2072408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
    Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
    Cascinu S; Fedeli A; Catalano G
    Cancer Chemother Pharmacol; 1994; 34(1):72-4. PubMed ID: 8174205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
    González-Barón M; Feliu J; Espinosa E; García-Girón C; Chacón I; Garrido P; Colmenarejo A; Ordóñez A; Zamora P
    Cancer Chemother Pharmacol; 1995; 36(3):255-8. PubMed ID: 7781148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
    Petrelli N; Herrera L; Rustum Y; Burke P; Creaven P; Stulc J; Emrich LJ; Mittelman A
    J Clin Oncol; 1987 Oct; 5(10):1559-65. PubMed ID: 2443619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
    Cascinu S; Silva RR; Labianca R; Barni S; Mattioli R; Martignoni G; Frontini L; Gasparini G; Catalano V; Baldelli AM; Giuliodori L; Agostinelli R; Catalano G
    Ann Oncol; 1999 Aug; 10(8):985-7. PubMed ID: 10509163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
    Look KY; Blessing JA; Valea FA; McGehee R; Manetta A; Webster KD; Andersen WA
    Gynecol Oncol; 1997 Dec; 67(3):255-8. PubMed ID: 9441772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk.
    Wilke H; Preusser P; Fink U; Achterrath W; Lenaz L; Stahl M; Schober C; Link H; Meyer HJ; Lucke B
    Invest New Drugs; 1990 Feb; 8(1):65-70. PubMed ID: 2345071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy.
    di Bartolomeo M; Bajetta E; de Braud F; Bochicchio AM; Gebbia V; Bozzetti F; Doci R; Bonfanti G; Cozzaglio L
    Oncology; 1995; 52(1):41-4. PubMed ID: 7800341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
    Di Costanzo F; Canaletti R; Sdrobolini A; Olmeo N; Luppi G; Pucci F; Cavicchi F; Gasperoni S; Rodinò C; Zironi S; Angiona S; Contu A
    Am J Clin Oncol; 2000 Jun; 23(3):314-8. PubMed ID: 10857901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
    Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
    J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.